Condition
Chronic Inflammatory Small Bowel Disease
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06189599UnknownPrimary
Modified antioxIdants Bacteria for Gut Inflammation
NCT04032756Terminated
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
NCT02797535Not ApplicableCompletedPrimary
GI Fluids Collection for an Ex-Vivo Development of Ingestible Capsule Devices With Real Time Biosensors
NCT02742714Not ApplicableCompletedPrimary
PillCam SBC System Functionality in Established and Suspected IBD Patients
Showing all 4 trials